Introduction
============

Angiogenesis is a complex biological process that plays an important role in sustaining growth, invasion, and the metastatic potential of tumors, and this process is mainly driven by vascular endothelial growth factor (VEGF).[@b1-ott-11-5059],[@b2-ott-11-5059] One of the VEGF family members, VEGF-A (commonly referred to as VEGF), has been demonstrated to be important in angiogenesis. Among all receptors, vascular endothelial growth factor receptor (VEGFR)-2 is widely thought to be principally linked to the stimuli of angiogenesis in malignancies. Blocking the function of VEGF-A or its receptor VEGFR-2 has been the most important antiangiogenic strategy for cancer therapy.[@b3-ott-11-5059]

Bevacizumab and ramucirumab are the most important antiangiogenic monoclonal antibodies, which target VEGF-A and its receptor VEGFR-2, respectively, used in various cancers. Bevacizumab is approved by the Food and Drug Administration (FDA) for the treatment of patients with metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer (NSCLC), metastatic renal cell carcinoma, recurrent glioblastoma, advanced cervical cancer, and platinum-resistant ovarian cancer, and ramucirumab is approved by the FDA for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma, metastatic NSCLC, and advanced colorectal cancer.

Bleeding events are a kind of major adverse events reported in clinical trials of bevacizumab and ramucirumab, which may cause severe outcomes that could be even life threatening.[@b4-ott-11-5059] The main mechanism of bleeding is that angio-genesis inhibitors disrupt tumor vasculature through inhibition of VEGF signaling and lead to thrombosis or bleeding.[@b1-ott-11-5059],[@b5-ott-11-5059]

However, the relative risk (RR) of bleeding events in patients with cancer treated with these two antiangiogenic monoclonal antibodies has yet to be defined. Therefore, we conducted an up-to-date meta-analysis of available clinical trials to determine the RR of bleeding in cancer patients treated with antiangiogenic monoclonal antibodies, bevacizumab and ramucirumab.

Materials and methods
=====================

Search strategy
---------------

This study was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement[@b6-ott-11-5059] ([Supplementary material](#SD1-ott-11-5059){ref-type="supplementary-material"}). We searched PubMed, American Society for Clinical Oncology Abstracts, and European Society for Medical Oncology Abstracts for relevant trials till September 2017. Moreover, we also searched the clinical trial registration website (<https://www.ClinicalTrials.gov>) to obtain information on registered randomized controlled trials (RCTs). Keywords used in the search were "bevacizumab," "avastin," "ramucirumab," "IMC1121B," "LY3009806," and "randomized controlled trials." The search was limited to RCTs published in English.

Selection of trials
-------------------

Data abstraction and quality assessment were conducted independently by two reviewers. Disagreements were resolved by discussion with an independent expert. The RCTs were eligible for inclusion in our meta-analysis: 1) prospective Phase II and Phase III RCTs in patients with cancer, 2) random assignment of participants to these two antiangiogenic monoclonal antibodies treatment or control groups, 3) available data, including the event or incidence of bleeding and sample size for analysis. Phase I and single-arm phase II trials were excluded because of their lack of control groups.

Data extraction
---------------

We extracted details on study characteristics, treatment information, results, and safety profiles from the selected trials. Clinical endpoints were obtained from the safety profile of each clinical trial. All-grade, high-grade bleeding and all-grade, high-grade pulmonary hemorrhage in lung cancers were recorded according to the version of National Cancer Institute-Common Terminology Criteria for Adverse Events used in each trial.

Statistical analysis
--------------------

Data were calculated by Review Manager version 5.2 (The Nordic Cochrane Centre, Copenhagen, Denmark). For the outcomes, the RR was calculated for dichotomous data. Statistical heterogeneity in the results of the trials was assessed by the chi-square test, and expressed by the *I*^2^ index.[@b7-ott-11-5059] When there was no statistically significant heterogeneity, a pooled effect was calculated with a fixed-effect model. When considerable heterogeneity was found (*p*\<0.1, or *I*^2^\>50%), a random-effect model was employed. Subgroup analysis was conducted to examine whether the RRs of all-grade and high-grade bleeding varied by drug type, drug dosage, and cancer type.

Results
=======

Search results
--------------

We reviewed 2,045 potentially relevant articles from our initial search strategies. A total of 1,906 articles were excluded on screening abstracts and titles for the following reasons: review articles, case reports, basic researches, Phase I or single-arm Phase II studies, irrelevant topics, and duplicate reports. The remaining 139 articles were retrieved for full evaluation, and 54 articles were excluded for unavailable data for assessment of bleeding or antiangiogenic monoclonal antibodies in both treatment and control arms. Finally, 85 RCTs were included in this meta-analysis.[@b8-ott-11-5059]--[@b92-ott-11-5059] The study search process is shown in a flow chart ([Figure 1](#f1-ott-11-5059){ref-type="fig"}).

Patients
--------

A total of 85 studies and 46,630 patients were included for the analysis. Bevacizumab was investigated in 72 trials[@b8-ott-11-5059]--[@b79-ott-11-5059] and ramucirumab was investigated in 13 trials.[@b80-ott-11-5059]--[@b92-ott-11-5059] All of the studies included 21 colorectal cancer,[@b8-ott-11-5059]--[@b26-ott-11-5059],[@b85-ott-11-5059],[@b86-ott-11-5059] 15 breast cancer,[@b27-ott-11-5059]--[@b39-ott-11-5059],[@b87-ott-11-5059],[@b88-ott-11-5059] 16 lung cancer,[@b40-ott-11-5059]--[@b52-ott-11-5059],[@b80-ott-11-5059]--[@b82-ott-11-5059] three renal cell cancer,[@b53-ott-11-5059],[@b54-ott-11-5059] two pancreatic cancer,[@b55-ott-11-5059],[@b56-ott-11-5059] five ovarian cancer,[@b57-ott-11-5059]--[@b61-ott-11-5059] six gastric or gastroesophageal junction adenocarcinoma,[@b62-ott-11-5059]--[@b65-ott-11-5059], [@b89-ott-11-5059]--[@b91-ott-11-5059] three glioblastoma,[@b66-ott-11-5059]--[@b68-ott-11-5059] one lymphoma,[@b69-ott-11-5059] one lymphocytic leukemia,[@b70-ott-11-5059] two melanoma,[@b71-ott-11-5059],[@b72-ott-11-5059] two malignant mesothelioma,[@b73-ott-11-5059],[@b74-ott-11-5059] one prostate cancer,[@b75-ott-11-5059] one cervical cancer,[@b76-ott-11-5059] one leiomyosarcoma,[@b77-ott-11-5059] two urothelial carcinoma,[@b83-ott-11-5059],[@b84-ott-11-5059] two hepatocellular carcinoma,[@b78-ott-11-5059],[@b92-ott-11-5059] and one soft tissue sarcoma.[@b79-ott-11-5059] In addition, 35 trials[@b9-ott-11-5059],[@b10-ott-11-5059],[@b12-ott-11-5059]--[@b20-ott-11-5059],[@b22-ott-11-5059]--[@b26-ott-11-5059],[@b46-ott-11-5059],[@b49-ott-11-5059],[@b52-ott-11-5059],[@b55-ott-11-5059],[@b58-ott-11-5059],[@b62-ott-11-5059]--[@b65-ott-11-5059],[@b72-ott-11-5059],[@b78-ott-11-5059]--[@b84-ott-11-5059],[@b87-ott-11-5059],[@b88-ott-11-5059] were treated with low-dose drugs (28 trials for bevacizumab at 2.5 mg/kg/week, seven trials for ramucirumab at 3.3 mg/kg/week) and 46 trials[@b11-ott-11-5059],[@b21-ott-11-5059],[@b27-ott-11-5059],[@b28-ott-11-5059],[@b30-ott-11-5059]--[@b39-ott-11-5059],[@b41-ott-11-5059],[@b42-ott-11-5059],[@b44-ott-11-5059],[@b45-ott-11-5059],[@b47-ott-11-5059],[@b48-ott-11-5059],[@b50-ott-11-5059],[@b51-ott-11-5059],[@b53-ott-11-5059],[@b54-ott-11-5059],[@b56-ott-11-5059],[@b57-ott-11-5059],[@b59-ott-11-5059]--[@b61-ott-11-5059],[@b66-ott-11-5059]--[@b71-ott-11-5059], [@b73-ott-11-5059]--[@b77-ott-11-5059],[@b85-ott-11-5059],[@b86-ott-11-5059],[@b89-ott-11-5059]--[@b92-ott-11-5059] were treated with high-dose drugs (40 trials for bevacizumab at 5 mg/kg/week, six trials for ramucirumab at 4 mg/kg/week). Other 4 three-arm trials[@b8-ott-11-5059],[@b29-ott-11-5059],[@b40-ott-11-5059],[@b43-ott-11-5059] were two arms of different dosage levels of bevacizumab and one arm of control. All of these RCTs were judged to be of adequate quality (Jadad score is 3--5). Baseline characteristics of the 85 RCTs are provided in [Table 1](#t1-ott-11-5059){ref-type="table"}.

RR of all-grade bleeding
------------------------

Forty-three RCTs were available to calculate the RR of all-grade bleeding in patients assigned to angiogenesis inhibitors arms versus control arms. The results showed that antiangiogenic monoclonal antibodies significantly increased the risk of all-grade (RR: 2.38, 95% CI: 2.09--2.71, *p*\<0.00001) bleeding compared with control arms. There was statistically significant heterogeneity (*I*^2^=74%) across the trials; we incorporated it into a random-effects model ([Figure 2](#f2-ott-11-5059){ref-type="fig"}).

RR of high-grade bleeding
-------------------------

The RR of high-grade (≥grade 3) bleeding was determined in 82 RCTs. The results showed that antiangiogenic monoclonal antibodies significantly increased the risk of all-grade bleeding (RR: 1.71, 95% CI: 1.48--1.97, *p*\<0.00001) with a fixed-effects models (*I*^2^=19%) ([Figure 3](#f3-ott-11-5059){ref-type="fig"}).

RR according to drug type
-------------------------

As an exploratory analysis, patients were stratified according to drug type. We found that bevacizumab significantly increased the risk of all-grade (RR: 2.73, 95% CI: 2.24--3.33, *p*\<0.00001) and high-grade bleeding (RR: 1.98, 95% CI: 1.68--2.34, *p*\<0.00001), but ramucirumab only increased the risk of all-grade bleeding (RR: 1.94, 95% CI: 1.76--2.13, *p*\<0.00001) and no difference was observed for the risk of high-grade bleeding (RR: 1.04, 95% CI: 0.78--1.39, *p*=0.79) compared with the control group. RR of all-grade and high-grade bleeding according to drug type is summarized in [Tables 2](#t2-ott-11-5059){ref-type="table"} and [3](#t3-ott-11-5059){ref-type="table"}, respectively.

In addition, we further assessed the risk of pulmonary hemorrhage of bevacizumab and ramucirumab in all lung cancer patients. The results showed that bevacizumab significantly increased the risk of all-grade (RR: 4.72, 95% CI: 1.99--11.19, *p*=0.0004) and high-grade pulmonary hemorrhage (RR: 3.97, 95% CI: 1.70--9.29, *p*=0.001), but no significant differences in the risk of all-grade (RR: 1.09, 95% CI: 0.76--1.57, *p*=0.64) and high-grade (RR: 1.22, 95% CI: 0.35--4.21, *p*=0.75) pulmonary hemorrhage were observed for ramucirumab. RR of all-grade and high-grade pulmonary hemorrhage is shown in [Figures 4](#f4-ott-11-5059){ref-type="fig"} and [5](#f5-ott-11-5059){ref-type="fig"}, respectively.

RR according to drug dosage
---------------------------

In the subgroup analysis by dosage, the increased risk of all-grade and high-grade bleeding was observed in both low-dose and high-dose angiogenesis inhibitors.

The risks of all-grade bleeding were comparable between patients with low-dose angiogenesis inhibitors (RR: 2.46, 95% CI: 1.95--3.11) and high-dose angiogenesis inhibitors (RR: 2.34, 95% CI: 2.00--2.73) ([Table 2](#t2-ott-11-5059){ref-type="table"}). The risk of high-grade bleeding was more frequently observed in patients with high-dose angiogenesis inhibitors (RR: 2.17, 95% CI: 1.79--2.64) than in those with low-dose angiogenesis inhibitors (RR: 1.31, 95% CI: 1.06--1.60) ([Table 3](#t3-ott-11-5059){ref-type="table"}).

RR according to tumor type
--------------------------

Studies were further stratified according to tumor type (colorectal cancer vs non-colorectal tumors). Increased risk of all-grade and high-grade bleeding was observed in both the colorectal cancer arm and non-colorectal tumors arm. The risks of all-grade (RRs for colorectal cancer and non-colorectal tumors were 2.24, 95% CI: 1.58--3.19 and 2.42, 95% CI: 2.09--2.80, respectively) ([Table 2](#t2-ott-11-5059){ref-type="table"}) and high-grade bleeding (RRs for colorectal cancer and non-colorectal tumors were 1.52, 95% CI: 1.13--2.03 and 1.77, 95% CI: 1.50--2.09, respectively) ([Table 3](#t3-ott-11-5059){ref-type="table"}) were comparable between patients with colorectal cancer and non-colorectal tumors.

Publication bias
----------------

To minimize publication bias, we selected papers strictly according to the inclusion criteria. Furthermore, a funnel plot was used to detect publication bias and no apparent bias was found according to it for all-grade and high-grade bleeding.

Discussion
==========

To the best of our knowledge, this is the first and the largest meta-analysis to assess the risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab. The results of our meta-analysis showed a significant 2.38-fold increased all-grade bleeding risk and a 1.71-fold increased high-grade bleeding risk with these agents. A similar risk of bleeding is also associated with other VEGF receptor tyrosine kinase inhibitors.[@b93-ott-11-5059]

In order to identify potential risk factors, we performed subgroup analysis according to drug types. The results showed that ramucirumab differed from bevacizumab in terms of the risk of high-grade bleeding and the risk of all-grade and high-grade pulmonary hemorrhage in lung cancer patients. The mechanisms underlying these differences remained unclear. A possible explanation was that bevacizumab, as an anti-VEGF-A agent, specified both VEGFR-1 and VEGFR-2, whereas ramucirumab was only specified for VEGFR-2. VEGFR-2 was the major mediator of VEGF-driven responses in endothelial cells. The precise function of VEGFR-1 was not entirely established and some studies showed that VEGFR-1 could also regulate proliferation and survival of endothelial cells.[@b94-ott-11-5059]--[@b97-ott-11-5059] Increased level of tumor VEGFR-1 expression has been shown to be associated with high tumor angiogenesis.[@b96-ott-11-5059] VEGF/VEGFR-1 signaling-mediated tumor cell monocyte chemoattractant protein-1 expression could represent a mechanism responsible for the tumor angiogenic switch.[@b97-ott-11-5059] Therefore, bevacizumab increased the risk of bleeding by inhibiting both VEGFR-1 and VEGFR-2. Squamous cell tumors are more frequently centrally located and have a greater tendency to cavitate as compared to adenocarcinoma, which is the main risk factor of pulmonary hemorrhage.[@b98-ott-11-5059] The difference in the risk of pulmonary hemorrhage caused bevacizumab to be used only for non-squamous NSCLC and ramucirumab to be used for any tumor histology of NSCLC.

Our study also demonstrated that both low-dose and high-dose angiogenesis inhibitors increased the risk of bleeding. The risk of high-grade bleeding was more frequently observed in patients with high-dose angiogenesis inhibitors, suggesting that the risk may be dose-dependent and close supervision and careful management should be emphasized especially in patients with high dosage.

In a meta-analysis of bevacizumab, patients with colorectal cancer were found to have the highest risk of bleeding compared to other tumors.[@b99-ott-11-5059] For colorectal cancer patients, high-grade bleeding such as perforation was commonly fatal and life threatening.[@b100-ott-11-5059] Therefore, we performed a subgroup analysis according to colorectal cancer and non-colorectal tumors in order to identify the potential risk factors. Results showed that the risk of all-grade and high-grade bleeding was comparable between patients with colorectal cancer and non-colorectal tumors, suggesting that the increased risk of bleeding is associated with many tumor types.

Limitations
===========

There are several limitations in this meta-analysis. First, we performed stratification analysis only for colorectal cancer and non-colorectal tumor types because too many tumor types were included in the analysis and assessment was difficult. Second, we did not evaluate the risk of pulmonary hemorrhage between bevacizumab and ramucirumab in lung squamous cell carcinoma patients due to the small sample size or absence of original data. Finally, our literature search was limited to articles published in English leading to some selection bias.

Conclusion
==========

Despite the limitations of our meta-analysis, we conclude that antiangiogenic monoclonal antibodies are associated with a significant increase in the risk of all-grade and high-grade bleeding. Ramucirumab may be different from bevacizumab in terms of the risk of high-grade bleeding and the risk of all-grade and high-grade pulmonary hemorrhage in lung cancer patients. Clinicians should be aware of this adverse effect and ensure close monitoring, especially in patients at high risk.

Supplementary material
======================
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PRISMA 2009 Checklist

  Section/topic                        \#   Checklist item                                                                                                                                                                                                                                                                                                Reported on page \#
  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  **Title**                                                                                                                                                                                                                                                                                                                                               
  Title                                1    Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                                                                                                           1
  **Abstract**                                                                                                                                                                                                                                                                                                                                            
  Structured summary                   2    Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.   2
  **Introduction**                                                                                                                                                                                                                                                                                                                                        
  Rationale                            3    Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                                3,4
  Objectives                           4    Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                                                                                                                    4
  **Methods**                                                                                                                                                                                                                                                                                                                                             
  Protocol and registration            5    Indicate if a review protocol exists, if and where it can be accessed (eg, Web address), and, if available, provide registration information including registration number.                                                                                                                                   
  Eligibility criteria                 6    Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years considered, language, publication status) used as criteria for eligibility, giving rationale.                                                                                                            4,5
  Information sources                  7    Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                      4
  Search                               8    Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                                 4
  Study selection                      9    State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                                                                                                       5
  Data collection process              10   Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                                      5
  Data items                           11   List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions and simplifications made.                                                                                                                                                                           5
  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                        5
  Summary measures                     13   State the principal summary measures (eg, risk ratio, difference in means).                                                                                                                                                                                                                                   5
  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (eg, I^2^) for each meta-analysis.                                                                                                                                                         5
  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias, selective reporting within studies).                                                                                                                                                                    5
  Additional analyses                  16   Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.                                                                                                                                                                5
  **Results**                                                                                                                                                                                                                                                                                                                                             
  Study selection                      17   Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                               6
  Study characteristics                18   For each study, present characteristics for which data were extracted (eg, study size, PICOS, follow-up period) and provide the citations.                                                                                                                                                                    6
  Risk of bias within studies          19   Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).                                                                                                                                                                                                     6
  Results of individual studies        20   For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.                                                                                                      7,8
  Synthesis of results                 21   Present results of each meta-analysis done, including confidence intervals and measures of consistency.                                                                                                                                                                                                       7,8
  Risk of bias across studies          22   Present results of any assessment of risk of bias across studies (see item 15).                                                                                                                                                                                                                               7,8
  Additional analysis                  23   Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-regression \[see item 16\]).                                                                                                                                                                                         7,8
  **Discussion**                                                                                                                                                                                                                                                                                                                                          
  Summary of evidence                  24   Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (eg, healthcare providers, users, and policy makers).                                                                                                                            9,10
  Limitations                          25   Discuss limitations at study and outcome level (eg, risk of bias), and at review-level (eg, incomplete retrieval of identified research, reporting bias).                                                                                                                                                     10
  Conclusions                          26   Provide a general interpretation of the results in the context of other evidence, and implications for future research.                                                                                                                                                                                       10,11
  **Funding**                                                                                                                                                                                                                                                                                                                                             
  Funding                              27   Describe sources of funding for the systematic review and other support (eg, supply of data); role of funders for the systematic review.                                                                                                                                                                      11

**Notes:** Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097. For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).
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###### 

Characteristics of studies included in the meta-analysis

  Author                                     Year   Malignancy             Phase     No. in intervention/control   Concurrent treatment                                                                                        Dose (mg/kg/week)   No. of bleeding events in intervention/control   
  ------------------------------------------ ------ ---------------------- --------- ----------------------------- ----------------------------------------------------------------------------------------------------------- ------------------- ------------------------------------------------ -------
  **Bevacizumab**                                                                                                                                                                                                                                                                                   
  Kabbinavar et al[@b8-ott-11-5059]          2003   CRC                    II        67/35                         Fluorouracil + leucovorin                                                                                   2.5 or 5            NR                                               3/0
  Hurwitz et al[@b9-ott-11-5059]             2004   CRC                    III       393/397                       Irinotecan + fluorouracil + leucovorin                                                                      2.5                 NR                                               12/10
  Kabbinavar et al[@b10-ott-11-5059]         2005   CRC                    II        100/104                       Fluorouracil + leucovorin                                                                                   2.5                 NR                                               5/3
  Giantonio et al[@b11-ott-11-5059]          2007   CRC                    III       287/285                       Oxaliplatin + fluorouracil + leucovorin                                                                     5                   NR                                               10/1
  Saltz et al[@b12-ott-11-5059]              2008   CRC                    III       694/675                       Capecitabine + oxaliplatin/fluorouracil + folinic acid + oxaliplatin                                        2.5                 NR                                               13/8
  Allegra et al[@b13-ott-11-5059]            2009   CRC                    III       1,326/1,321                   Oxaliplatin + fluorouracil + leucovorin                                                                     2.5                 NR                                               25/25
  Tebbutt et al[@b14-ott-11-5059]            2010   CRC                    III       157/156                       Capecitabine                                                                                                2.5                 19/19                                            2/4
  Statopoulos et al[@b15-ott-11-5059]        2010   CRC                    III       114/108                       Irinotecan + fluorouracil + leucovorin                                                                      2.5                 3/0                                              NR
  Guan et al[@b16-ott-11-5059]               2011   CRC                    III       141/70                        Irinotecan + fluorouracil + leucovorin                                                                      2.5                 NR                                               1/1
  Dotan et al[@b17-ott-11-5059]              2012   CRC                    II        12/11                         Capecitabine + oxaliplatin + cetuximab                                                                      2.5                 6/4                                              0/0
  De Gramont et al[@b18-ott-11-5059]         2012   CRC                    III       1,145/1,126                   Oxaliplatin + fluorouracil + leucovorin                                                                     2.5                 NR                                               14/6
  Bennouna et al[@b19-ott-11-5059]           2013   CRC                    III       401/409                       Fluorouracil/capecitabine + oxaliplatin/irinotecan                                                          2.5                 NR                                               8/1
  Cunningham et al[@b20-ott-11-5059]         2013   CRC                    III       134/136                       Capecitabine                                                                                                2.5                 34/9                                             0/1
  Cao et al[@b21-ott-11-5059]                2015   CRC                    II        65/77                         Irinotecan + fluorouracil + leucovorin                                                                      5                   NR                                               5/0
  Hegewisch-Becker et al[@b22-ott-11-5059]   2015   CRC                    III       156/158                       None                                                                                                        2.5                 14/11                                            0/1
  Passardi et al[@b23-ott-11-5059]           2015   CRC                    III       176/194                       Irinotecan + fluorouracil + leucovorin/oxaliplatin + fluorouracil + leucovorin                              2.5                 30/9                                             NR
  Masi et al[@b24-ott-11-5059]               2015   CRC                    III       91/92                         Irinotecan + fluorouracil + leucovorin/oxaliplatin + fluorouracil + leucovorin                              2.5                 19/2                                             0/0
  Koeberle et al[@b25-ott-11-5059]           2015   CRC                    III       131/131                       None                                                                                                        2.5                 5/1                                              0/0
  Snoeren et al[@b26-ott-11-5059]            2017   CRC                    III       39/36                         Capecitabine + oxaliplatin                                                                                  2.5                 NR                                               0/1
  Miller et al[@b27-ott-11-5059]             2005   BC                     III       229/215                       Capecitabine                                                                                                5                   66/24                                            1/1
  Miller et al[@b28-ott-11-5059]             2007   BC                     III       365/346                       Paclitaxel                                                                                                  5                   NR                                               2/0
  Miles et al[@b29-ott-11-5059]              2010   BC                     III       499/231                       Docetaxel                                                                                                   2.5 or 5            NR                                               5/2
  Brufsky et al[@b30-ott-11-5059]            2011   BC                     III       458/221                       Capecitabine/taxane/gemcitabine/vinorelbine                                                                 5                   NR                                               8/0
  Robert et al[@b31-ott-11-5059]             2011   BC                     III       817/403                       Capecitabine/taxane/anthracycline                                                                           5                   NR                                               14/1
  von Minckwitz et al[@b32-ott-11-5059]      2012   BC                     III       956/969                       Epirubicin/cyclophosphamide/docetaxel                                                                       5                   NR                                               4/3
  Gianni et al[@b33-ott-11-5059]             2013   BC                     III       215/206                       Docetaxel + trastuzumab                                                                                     5                   NR                                               3/1
  Cameron et al[@b34-ott-11-5059]            2013   BC                     III       1,288/1,271                   Anthracycline/taxane                                                                                        5                   NR                                               8/2
  Coudert et al[@b35-ott-11-5059]            2014   BC                     II        47/25                         Trastuzumab + docetaxel                                                                                     5                   NR                                               0/0
  von Minckwitz et al[@b36-ott-11-5059]      2014   BC                     III       245/238                       Taxane/anthracycline/capecitabine/vinorelbine/gemcitabin/cyclophosphamide                                   5                   33/18                                            1/4
  Sikov et al[@b37-ott-11-5059]              2015   BC                     II        215/218                       Paclitaxel ± carboplatin--doxorubicin + cyclophosphamide                                                    5                   NR                                               7/0
  Diéras et al[@b38-ott-11-5059]             2015   BC                     II        56/57                         Trebananib + paclitaxel                                                                                     5                   29/17                                            0/0
  Miles et al[@b39-ott-11-5059]              2017   BC                     III       238/233                       Paclitaxel                                                                                                  5                   106/62                                           2/2
  Johnson et al[@b40-ott-11-5059]            2004   LC                     II        66/32                         Carboplatin + paclitaxel                                                                                    2.5 or 5            NR                                               6/0
  Sandler et al[@b41-ott-11-5059]            2006   LC                     III       427/440                       Paclitaxel + carboplatin                                                                                    5                   NR                                               19/3
  Herbst et al[@b42-ott-11-5059]             2007   LC                     II        39/42                         Docetaxel/pemetrexed                                                                                        5                   NR                                               3/1
  Reck et al[@b43-ott-11-5059]               2009   LC                     III       659/327                       Cisplatin + gemcitabine                                                                                     2.5 or 5            NR                                               28/6
  Herbst et al[@b44-ott-11-5059]             2011   LC                     III       313/313                       Erlotinib                                                                                                   5                   NR                                               10/7
  Niho et al[@b45-ott-11-5059]               2012   LC                     II        119/58                        Carboplatin + paclitaxel                                                                                    5                   94/18                                            2/0
  Boutsikou et al[@b46-ott-11-5059]          2013   LC                     III       116/113                       Docetaxel + carboplatin ± erlotinib                                                                         2.5                 7/0                                              3/0
  Seto et al[@b47-ott-11-5059]               2014   LC                     II        75/77                         Erlotinib                                                                                                   5                   54/22                                            2/0
  Zhou et al[@b48-ott-11-5059]               2015   LC                     III       140/134                       Carboplatin, paclitaxel                                                                                     5                   NR                                               2/1
  Pujol et al[@b49-ott-11-5059]              2015   LC                     II--III   37/37                         Cisplatin + etoposide ± epidoxorubicin + cyclophosphamide                                                   2.5                 7/2                                              0/0
  Takeda et al[@b50-ott-11-5059]             2016   LC                     II        50/50                         Docetaxel                                                                                                   5                   20/3                                             0/0
  Karayama et al[@b51-ott-11-5059]           2016   LC                     II        45/35                         Pemetrexed                                                                                                  5                   NR                                               0/0
  Tiseo et al[@b52-ott-11-5059]              2017   LC                     III       95/103                        Cisplatin + etoposide                                                                                       2.5                 NR                                               0/0
  Escudier et al[@b53-ott-11-5059]           2007   RCC                    III       337/304                       Interferon α                                                                                                5                   112/28                                           11/1
  Rini et al[@b54-ott-11-5059]               2010   RCC                    III       362/347                       Interferon α                                                                                                5                   21/4                                             4/1
  Van Cutsem et al[@b55-ott-11-5059]         2009   PC                     III       296/287                       Gemcitabine + erlotinib                                                                                     2.5                 124/67                                           22/16
  Kindler et al[@b56-ott-11-5059]            2010   PC                     III       277/263                       Gemcitabine                                                                                                 5                   NR                                               5/4
  Burger et al[@b57-ott-11-5059]             2011   OC                     III       608/601                       Paclitaxel + carboplatin                                                                                    5                   NR                                               14/5
  Perren et al[@b58-ott-11-5059]             2011   OC                     III       745/753                       Paclitaxel + carboplatin                                                                                    2.5                 295/87                                           9/2
  Pujade-Lauraine et al[@b59-ott-11-5059]    2014   OC                     III       179/181                       PLD/paclitaxel/topotecan                                                                                    5                   NR                                               2/2
  Aghajanian et al[@b60-ott-11-5059]         2015   OC                     III       247/233                       Gemcitabine + carboplatin                                                                                   5                   170/78                                           15/2
  Coleman et al[@b61-ott-11-5059]            2017   OC                     III       330/327                       Paclitaxel + carboplatin                                                                                    5                   140/27                                           6/3
  Ohtsu et al[@b62-ott-11-5059]              2011   GC                     III       386/381                       Cisplatin + capecitabine                                                                                    2.5                 NR                                               9/9
  Okines et al[@b63-ott-11-5059]             2013   GC                     II/III    99/101                        Epirubicin + cisplatin + capecitabine                                                                       2.5                 NR                                               1/3
  Shen et al[@b64-ott-11-5059]               2015   GC, GEJC               III       100/101                       Capecitabine + cisplatin                                                                                    2.5                 NR                                               12/4
  Cunningham et al[@b65-ott-11-5059]         2017   GEJC                   II/III    468/477                       Epirubicin + cisplatin + capecitabine                                                                       2.5                 15/7                                             2/2
  Chinot et al[@b66-ott-11-5059]             2014   Glioblastoma           III       461/450                       Radiotherapy + temozolomide                                                                                 5                   186/97                                           15/8
  Gilbert et al[@b67-ott-11-5059]            2014   Glioblastoma           III       260/233                       None                                                                                                        5                   NR                                               4/2
  Balana et al[@b68-ott-11-5059]             2016   Glioblastoma           II        48/45                         Temozolomide                                                                                                5                   NR                                               5/0
  Seymour et al[@b69-ott-11-5059]            2014   Lymphoma               III       395/386                       Rituximab + doxorubicin + vincristine + cyclophosphamide + prednisone instead of R-CHOP                     5                   77/31                                            8/1
  Kay et al[@b70-ott-11-5059]                2016   Lymphocytic leukemia   II        33/32                         Pentostatin + cyclophosphamide + rituximab                                                                  5                   NR                                               1/0
  Kim et al[@b71-ott-11-5059]                2012   Melanoma               II        143/69                        Paclitaxel + carboplatin                                                                                    5                   NR                                               2/5
  Corrie et al[@b72-ott-11-5059]             2014   Melanoma               III       671/672                       None                                                                                                        2.5                 153/13                                           1/1
  Kindler et al[@b73-ott-11-5059]            2012   MM                     II        53/55                         Gemcitabine + cisplatin                                                                                     5                   NR                                               4/1
  Zalcman et al[@b74-ott-11-5059]            2016   MM                     III       222/224                       Pemetrexed + cisplatin                                                                                      5                   91/16                                            2/0
  Kelly et al[@b75-ott-11-5059]              2012   Prostate cancer        III       504/505                       Docetaxel + prednisone                                                                                      5                   NR                                               35/16
  Tewari et al[@b76-ott-11-5059]             2014   Cervical cancer        III       220/219                       Paclitaxel/topotecan + cisplatin                                                                            5                   NR                                               10/2
  Hensley et al[@b77-ott-11-5059]            2015   uLMS                   III       52/51                         Gemcitabine + docetaxel                                                                                     5                   1/2                                              0/1
  Pinter et al[@b78-ott-11-5059]             2015   HC                     II        16/11                         TACE                                                                                                        2.5                 3/1                                              3/1
  Chisholm et al[@b79-ott-11-5059]           2017   STSs                   II        71/79                         Ifosfamide + vincristine + actinomycin-D + doxorubicin instead of VADO/IVA/cyclophosphamide + vinorelbine   2.5                 NR                                               2/6
  **Ramucirumab**                                                                                                                                                                                                                                                                                   
  Yoh et al[@b80-ott-11-5059]                2016   LC                     II        76/81                         Docetaxel                                                                                                   3.3                 39/23                                            2/0
  Doebele et al[@b81-ott-11-5059]            2015   LC                     II        67/69                         Pemetrexed + cisplatin                                                                                      3.3                 26/13                                            2/1
  Garon et al[@b82-ott-11-5059]              2014   LC                     III       627/618                       Docetaxel                                                                                                   3.3                 181/94                                           15/14
  Petrylak et al[@b83-ott-11-5059]           2016   UC                     II        46/45                         Docetaxel                                                                                                   3.3                 31/12                                            2/1
  Petrylak et al[@b84-ott-11-5059]           2017   UC                     III       263/267                       Docetaxel                                                                                                   3.3                 67/46                                            8/12
  Tabernero et al[@b85-ott-11-5059]          2015   CRC                    III       529/528                       None                                                                                                        4                   232/120                                          13/9
  Moore et al[@b86-ott-11-5059]              2016   CRC                    II        52/49                         Oxaliplatin + fluorouracil + leucovorin                                                                     4                   25/9                                             NR
  Mackey et al[@b87-ott-11-5059]             2015   BC                     III       752/382                       Docetaxel                                                                                                   3.3                 361/85                                           7/7
  Yardley et al[@b88-ott-11-5059]            2016   BC                     II        69/65                         Eribulin                                                                                                    3.3                 13/3                                             1/1
  Fuchs et al[@b89-ott-11-5059]              2014   GC or GEJC             III       236/115                       None                                                                                                        4                   30/13                                            8/3
  Wilke et al[@b90-ott-11-5059]              2014   GC or GEJC             III       327/329                       Paclitaxel                                                                                                  4                   137/59                                           14/8
  Yoon et al[@b91-ott-11-5059]               2016   GC, EC, or GEJC        II        82/80                         Oxaliplatin + fluorouracil + leucovorin                                                                     4                   36/20                                            5/5
  Zhu et al[@b92-ott-11-5059]                2015   HC                     III       277/276                       None                                                                                                        4                   90/55                                            17/21

**Abbreviations:** CRC, colorectal cancer; BC, breast cancer; LC, lung cancer; RCC, renal cell carcinoma; PC, pancreatic cancer; OC, ovarian cancer; GC, gastric cancer; MM, malignant mesothelioma; uLMS, uterine leiomyosarcoma; UC, urothelial carcinoma; EC, esophagus cancer; GEJC, gastroesophageal junction cancer; HC, hepatocellular carcinoma; STSs, soft tissue sarcomas; NR, not reached; TACE, transarterial chemoembolization.

###### 

RR of all-grade bleeding associated with angiogenesis inhibitors in the subgroup analysis

  Bleeding                No. of trials   No. of events/total (%)   RR, 95% CI           
  ----------------------- --------------- ------------------------- -------------------- ------------------
  **Type of drug**                                                                       
  Bevacizumab             30              1,934/6,738 (28.7)        679/6,586 (10.3)     2.73, 2.24--3.33
  Ramucirumab             13              1,268/3,403 (37.3)        552/2,904 (19.0)     1.94, 1.76--2.13
  **Drug dosage**                                                                        
  Low dose                22              1,452/5,220 (27.8)        508/4,863 (10.4)     2.46, 1.95--3.11
  High dose               21              1,750/4,921 (35.6)        723/4,627 (15.6)     2.34, 2.00--2.73
  **Tumor types**                                                                        
  Colorectal cancer       10              387/1,552 (24.9)          184/1,563 (11.8)     2.24, 1.58--3.19
  Non-colorectal cancer   33              2,815/8,589 (32.8)        1,047/7,927 (13.2)   2.42, 2.09--2.80

**Abbreviation:** RR, relative risk.

###### 

RR of high-grade bleeding associated with angiogenesis inhibitors in the subgroup analysis

  Bleeding                No. of trials   No. of events/total (%)   RR, 95% CI         
  ----------------------- --------------- ------------------------- ------------------ ------------------
  **Type of drug**                                                                     
  Bevacizumab             70              432/20,731 (2.1)          194/19,000 (1.0)   1.98, 1.68--2.34
  Ramucirumab             12              94/3,351 (2.8)            82/2,855 (2.9)     1.04, 0.78--1.39
  **Drug dosage**                                                                      
  Low dose                37              203/10,569 (1.9)          149/10,089 (1.5)   1.31, 1.06--1.60
  High dose               49              323/13,513 (2.4)          135/12,391 (1.1)   2.17, 1.79--2.64
  **Tumor types**                                                                      
  Colorectal cancer       18              111/5,868 (1.9)           71/5,747 (1.2)     1.52, 1.13--2.03
  Non-colorectal cancer   64              415/18,214 (2.3)          205/16,108 (1.3)   1.77, 1.50--2.09

**Abbreviation:** RR, relative risk.
